In the phase I EV‐101 study, which enrolled metastatic urothelial carcinoma patients with Nectin‐4‐positive tumours, who had previously received ICI therapy, EV demonstrated a superior objective response rate (ORR) of 43% [1]. This evidence concerns the gene NECTIN4 and neoplasm.